tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Positive Outlook and Strategic Growth Plans Bolster Thermo Fisher’s Stock Rating

Positive Outlook and Strategic Growth Plans Bolster Thermo Fisher’s Stock Rating

Puneet Souda, an analyst from Leerink Partners, reiterated the Buy rating on Thermo Fisher. The associated price target is $500.00.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Puneet Souda’s rating is based on a combination of factors that suggest a positive outlook for Thermo Fisher’s stock. The company recently adjusted its long-range plan (LRP) for organic growth, setting a new target of over 7%, which was a strategic move that seemed to boost investor confidence. This adjustment, announced earlier than expected, has set a foundation for potential stock recovery, indicating that the company is positioning itself for future growth.
Moreover, despite some challenges in the early-stage discovery market, Thermo Fisher is benefiting from strong late-stage pharma and biotech trial activities. The company’s management has also provided a new framework for 2026 and 2027, projecting organic growth rates and EBIT margin expansion that align with or exceed market expectations. These strategic plans, along with a positive outlook on pharma spending and R&D intensity, underpin Souda’s Buy rating, reflecting confidence in Thermo Fisher’s ability to navigate current market conditions and achieve long-term growth.

Souda covers the Healthcare sector, focusing on stocks such as Quanterix, Exact Sciences, and Illumina. According to TipRanks, Souda has an average return of -10.3% and a 30.51% success rate on recommended stocks.

In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $523.00 price target.

Disclaimer & DisclosureReport an Issue

1